Questa linea guida pubblicata da NICE, riguarda la diagnosi, il monitoraggio e […]
Search Results for: FDA approva un nuovo trattamento per l’emicrania
Here's what we've found for you
FDA Authorizes First At-Home COVID-19 and Flu Combo Test
The US Food and Drug Administration (FDA) recently granted authorization to market the first at-home influenza and COVID-19 combination test outside of emergency use.
Medication Abortion Through Telehealth Is Safe and Effective
In 2000, the US Food and Drug Administration (FDA) approved the medication mifepristone, an antiprogesterone oral medication used with misoprostol to induce abortion. Before mifepristone, most abortions that occurred within the medical system in the US were done using either procedural abortion or medication abortion that used methotrexate or misoprostol only, both of which can have higher adverse event profiles and lower efficacy rates than the mifepristone-misoprostol combined regimen. Mifepristone’s approval advanced treatment options for patients needing abortion care and those undergoing miscarriage management, improved the efficacy and availability of medication abortion, and increased the power of patients to manage their own abortions in the place and time of their choosing.
Impacts of Immunotherapy on Patients With Aggressive Thyroid Carcinomas
Immunotherapy has represented a novel and cutting-edge approach to treating patients with many types of metastatic cancers in recent years, transforming outcomes for patients who previously had limited options. Immunotherapy enhances the body’s natural defenses to target and eliminate cancer cells. The agents used are immune checkpoint inhibitors that target specific sites within the immune system, particularly focusing on T cells and their interactions with cancer cells or antigen-presenting cells. The primary sites at T cells of action include the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis and cytotoxic T-lymphocyte–associated protein 4 (CTLA-4). The US Food and Drug Administration (FDA) has approved several immunotherapy agents, and each could have different modes of action targeting these sites in various cancers. In 2020, pembrolizumab, a PD-1 inhibitor, was approved for the treatment of patients with anaplastic thyroid carcinoma. In 2 nonrandomized phase 2 clinical trials in this issue of JAMA Oncology, Sehgal et al and Cabanillas et al explored the applications of immunotherapy in treating patients with aggressive thyroid cancer.
Il cda dell'Aifa approva la rimborsabilità di 16 farmaci
Tre orfani, 7 nuovi e 6 estensioni delle indicazioni terapeutiche
Linee guida melanoma
La Linea guida AIOM Melanoma ha lo scopo di formulare […]
Linee guida tumori delle vie biliari
L’AIOM ha pubblicato nel 2019 le Linee guida sulla classificazione […]
Linee guida carcinoma dell’ovaio
Le Linee Guida AIOM CARCINOMA DELL’OVAIO hanno lo scopo di […]
Linee guida e addendum neoplasie dello stomaco e della giunzione esofago-gastrica
Le Linee Guida AIOM Stomaco e giunzione gastro-esofagea hanno lo […]
Linee guida carcinoma della prostata
Le Linee guida AIOM Carcinoma della prostata hanno lo scopo […]
Linee guida neoplasie dell’utero: endometrio e cervice
La Linea Guida AIOM Tumori dell’Utero ha lo scopo di […]
Linee guida neoplasia della mammella
Le Linee Guida AIOM Neoplasie della Mammella hanno lo scopo […]
Linee guida tumori del rene
La Linea Guida AIOM Tumori del Rene ha lo scopo […]
Linee guida neoplasia del polmone
Le Linee guida AIOM Neoplasie del polmone hanno lo scopo […]
Linee guida carcinoma del pancreas esocrino
Le Linee guida AIOM sul Carcinoma del pancreas hanno lo […]
Linee guida tumori del colon
Le Linee guida AIOM Tumori del colon hanno lo scopo […]